Navigation Links
ChemoFx® Drug Response Marker Delivers Substantial Cost Savings
Date:6/3/2010

PITTSBURGH, June 3 /PRNewswire/ -- A study demonstrating the cost savings realized through the use of the ChemoFx® Drug Response Marker for assisting selection of treatment in recurrent ovarian cancer was published recently in the American Journal of Obstetrics and Gynecology (AJOG).

This economic analysis of recurrent ovarian cancer patients studied the direct costs of chemotherapy for three groups; empiric, assay-assisted, and assay-adherent. This study demonstrated that ChemoFx®-assisted chemotherapy may result in substantially reduced costs compared with empiric therapy.

The publication, titled, "Impact of a Chemoresponse Assay on Treatment Costs for Recurrent Ovarian Cancer," evaluated the net cost savings associated with the use of the ChemoFx® drug response marker to aid therapeutic decisions in the setting of recurrent ovarian cancer, and reveals a possible cost savings of $15,600 to $24,800.  

"In this tough economic time it is exciting to see cost savings resulting from the personalized information provided by ChemoFx® for cancer patients, physicians and the health care system," said Sean McDonald, CEO of Precision Therapeutics.  

About Precision Therapeutics

Precision Therapeutics, a life sciences company and leader in the development of innovative technology, delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions for patients with cancer.  

Precision's ChemoFx®, a proprietary drug response marker, measures an individual patients' tumor response to a range of therapeutic alternatives under consideration by a physicia
'/>"/>

SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
3. Directors Forum: PEPFAR and the Global AIDS Response
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
6. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
7. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
8. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
9. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
10. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
11. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 With ... cytometry is experiencing a rise in active partnerships. ... in underdeveloped nations to quantitate CD4 cell markers ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... the Global Flow Cytometry Market ( http://www.frost.com/nf0e ), ...
(Date:8/31/2015)...  The departments of Drug and Alcohol Programs (DDAP) ... 90 to raise awareness for International Overdose Awareness Day ... Pennsylvania and help more Pennsylvanians with substance ... the Building Bridges to Recovery initiative. ... to a disease that is fully treatable, if given ...
(Date:8/31/2015)... Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest independent ... & CEO, and Sean Whelan , CFO, will present ... and Mr. Whelan are scheduled to participate in the Wells ... on Wednesday, September 9, 2015 at 1:45 PM ET. ... participate in the Robert W. Baird 2015 Healthcare Conference in ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2
... LOS ANGELES--(BUSINESS WIRE)--May 21, 2007 - Cougar Biotechnology,Inc. ... Phase,II data on the Company's prostate cancer drug ... Urological,Association (AUA) Annual Meeting, which is currently taking ... Dr. Timothy A.,Yap from the Cancer Research UK ...
... WIRE)--May 21, 2007 - Medical,professionals seeking to ... gram-negative pneumonia may have a new weapon:,NKTR-061 ... by Nektar Therapeutics (Nasdaq:NKTR)., Results of a ... of,NKTR-061 (Inhaled Amikacin) to treat mechanically ventilated,patients ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... interviewed dating men and pick-up artists about their experiences of female beauty, women’s ... bodily concerns, including penis issues, as well as their relationships with other men, ...
(Date:9/1/2015)... ... ... every family has them. Whether it’s a morning routine, meal time routine or weekly ... Here are three reasons why routines can be beneficial for a child: , 1. ... implemented into a child’s schedule, they are able to anticipate what will happen next ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, ... safety labels and stickers to keep little ones' safety top of mind at all ... has a particular focus. According to the JPMA's Baby Safety Zone website, this year's ...
(Date:9/1/2015)... ... September 01, 2015 , ... Curly Hair Solutions™ is ... This highly anticipated partnership between Curly Hair Solutions™ and Trade Secrets allows for ... Torch and the Curly Hair Solutions™ team could not be more delighted to ...
(Date:8/31/2015)... (PRWEB) , ... September 01, 2015 , ... ... to eliminate chronic back pain – once required a long, arduous recovery. However, ... hospital stay, less pain, less blood loss and minimal muscle damage. These advantages ...
Breaking Medicine News(10 mins):Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4
... India have criticized the recent announcement of health ... ,Mr.Vinay Agarwal, Secretary of Indian medical Association // that ... of adding ayurveda, unani and homoeopathy subjects in the ... anybody,", ,He added: "The move would also lead ...
... stress can affect younger men with clogged arteries leading to ... in the current issue of Psychosomatic Medicine. However, women in ... tendencies, said the study., ,The researchers from University of ... of the carotid arteries, which supply blood to the head, ...
... The field of genetics has been undergoing a revolution ... common disorders and a huge amount of resources allocated ... ,This has not only added motivation to scientists working ... replace the existing knowledge with those acquired new. One ...
... bred a new kind of rat that will help them ... postmenopausal women that can lead to hypertension and heart failure., ... have created a better research rat by changing a single ... them to study salt-sensitivity in hypertension as well as explore ...
... way is a judgement to popularise smoking but a simple stating ... National Institutes of Health and the Centre for Disease Control, // ... fresh cause of concern for anti-smoking lobbies and doctors. As smoking ... says that people who smoke are less likely to visit the ...
... by new virus-induced diseases like bird flu and Japanese ... specialization in virology. The NIV and the Institute of ... would confer the degree jointly., ,"There is a ... outbreak. The course is intended to provide qualified virologists ...
Cached Medicine News:Health News:Launch Of India’s First Virology Course At Pun 2
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma....
... is comprised of the TEG analyzer and the ... picture of the formation and dissolution of the ... two systems. ,Haemoscope's TEG analyzer is the only ... the reliable and proven model developed by Prof. ...
With BareWire technology, the wire crosses the lesion first, independent of the filter and delivery catheter. All other actions, including filter placement and retrieval, balloon dilatations, and ste...
... is supported on NT / 2000 platforms. ... to effectively work in a multi-user, networked ... move comfortably to an enhanced level of ... improving the quality of patient care. , ...
Medicine Products: